KMRtype® / KMRtrack®

Comprehensive solution for chimerism study by qPCR, combining pre-transplant genetic typing kits and post-transplant quantitative monitoring.

Detailed Description

KMRtype® and KMRtrack® are complementary systems developed by GenDx for the characterization and monitoring of chimerism in transplant patients, using qPCR-based assays. The system allows everything from the identification of unique informative markers between recipient and donor, to the precise quantification of reference DNA in post-transplant samples.

KMRtype and KMRtrack KMRtype and KMRtrack Analysis

KMRtype® is a genetic typing kit that allows the selection of informative markers between recipient and donor DNA. Each mix contains three multiplexed primers and is used in pre-transplant settings. The kits are available in Core (30 assays in 10 mixes) and Extended (15 assays in 5 additional mixes) versions, allowing coverage of up to 45 assays in total. This phase is essential to identify which specific markers can be used effectively for monitoring.

KMRtrack and KMRengine

KMRtrack® is used for post-transplant monitoring using singleplex qPCR assays. Each marker selected in the typing phase is used to quantify the proportion of reference DNA (either from the recipient or the donor) in the samples, allowing precise monitoring of the patient’s chimeric status over time. The achieved limit of detection is 0.05%, depending on the amount of DNA used.

Both kits are optimized for use alongside the KMRengine® software, which guides experimental setup, manages qPCR plates, analyzes results, and automatically reports the chimerism percentage. The platform allows registering multiple samples, designing customized experiments, and visualizing data graphically and chronologically.

Performance and Validation

Validation studies showed 100% accuracy in typing and high intra- and inter-batch reproducibility in monitoring. Specificity was confirmed for all markers. Detection tests indicated that the system maintains robust performance with variable amounts of DNA, making it ideal for both clinical and experimental samples.

Important Considerations

Use with non-human DNA or cfDNA is not recommended. The use of at least two informative markers is recommended to avoid false results. Reagents are light-sensitive and must be stored at -20 °C. Heparinized samples should not be used, as they interfere with PCR. It is necessary to physically separate pre- and post-PCR areas to avoid cross-contamination.

Clinical Applications

This system is indicated for chimerism studies in the context of hematopoietic stem cell transplantation, with special utility in graft monitoring and early detection of relapse. Its sensitivity allows the detection of minimal amounts of donor or recipient-derived DNA, facilitating early therapeutic decisions.

Key Features

Complete system for chimerism typing and monitoring using qPCR.
Identification of specific informative markers for each donor-recipient pair.
Chimerism detection with sensitivity down to 0.05%.
Optimized protocols for genomic DNA from blood.
Automated analysis with KMRengine® software.
High inter-batch reproducibility and accuracy.
Compatible with multiple validated qPCR systems.

Ordering Information

KMRtype® RUO & CE-IVD: Core Mixes (30 assays, 24 samples) – Ref. 8341161 / Extended Mixes (15 assays, 24 samples) – Ref. 8341561 KMRtrack® RUO & CE-IVD: Core and Extended Kits, 48 reactions per assay – Ref. 8344162 and 8344562 KMRassay: Reference Assay (REF901) and Buffer & Enzyme – 288 reactions – Ref. 8343264 and 8343263 Versions also available as CE-IVD (see specific references in the IFU) For use with KMRengine® software (included in the GenDx platform) Store at -20 °C, protected from light

Area:

Bone marrow (chimerism), Immunology, Post transplantation

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Franklin by QIAGEN for Somatic Analysis

Advanced cloud-based bioinformatics platform designed for the automated analysis, interpretation, and classification of somatic variants in oncology. Through an integrated environment, the system evaluates clinical evidence in real time, automates classification in accordance with AMP/ASCO/CAP guidelines, and provides access to currently active clinical trials. Detailed description Operating principle End-to-end cloud-based solution for the clinical interpretation…
Qiagen
Next Generation Sequencing (NGS)

SeqOne Genomics – Somatic

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow. Detailed description Operating principle SeqOne Genomics is a genomic data…
SeqOne
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)